Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

ABSTRACT:

Purpose

Antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway have yielded more modest clinical benefit to patients with non-small-cell lung cancer (NSCLC) than initially expected. Clinical data suggest a distinct biologic role of the VEGF pathway in the different histologic subtypes of lung cancer. To clarify the influence of histologic differentiation in the prognostic relevance of VEGF-mediated signaling in NSCLC, we performed a concomitant analysis of the expression of three key elements of the VEGF pathway in the earliest stages of the following two principal histologic subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (ADC).

Patients and methods

We evaluated tumor cell expression of VEGF, VEGF receptor (VEGFR) 1, and VEGFR2 u

SUBMITTER: Pajares MJ 

PROVIDER: S-EPMC4874209 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature